CGEN | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 8%

Liquidity 40%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.69%

1 Month

30.99%

3 Months

40.00%

6 Months

60.00%

1 Year

38.27%

2 Year

-19.42%

Key data

Stock price

$2.24

P/E Ratio

0.00

DAY RANGE

$2.10 - $2.24

EPS

-$0.40

52 WEEK RANGE

$1.13 - $2.38

52 WEEK CHANGE

$33.33

MARKET CAP

171.517 M

YIELD

N/A

SHARES OUTSTANDING

89.532 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-19-2025

BETA

2.35

PUBLIC FLOAT

AVERAGE 10 VOLUME

$558,453

AVERAGE 30 VOLUME

$307,714

Company detail

CEO: Anat Cohen-Dayag
Region: US
Website: cgen.com
Employees: 70
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Compugen Ltd. researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, are in clinical study in patients with advanced or metastatic non-small cell lung cancer.

CGEN - COMPUGEN LTD